<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871310</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/030815</org_study_id>
    <nct_id>NCT02871310</nct_id>
  </id_info>
  <brief_title>Vasoactive Effects of IQP-AS-118 in Healthy Individuals</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Monocenter, Crossover Investigation to Evaluate the Vasoactive Effects of IQP-AS-118 in Healthy Individuals: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the benefit of IQP-AS-118 on the vasoactive
      effects in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EndoPAT (chronic effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pre-dose at the end vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EndoPAT (acute effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ex vivo blood platelet aggregation / adhesion (acute effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ex vivo blood platelet aggregation / adhesion pre-dose (chronic effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood coagulation / clotting parameters (acute effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood coagulation / clotting parameters predose (chronic effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of benefit</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by the subjects and investigator at end of each intervention (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SF- 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>12 weeks</time_frame>
    <description>End of each intervention vs. screening (Week 4 vs. screening, week 12 vs. screening) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (Week 4 vs. week 0, week 12 vs. week 8) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (Week 4 vs. week 0, week 12 vs. week 8) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (Week 4 vs. week 0, week 12 vs. week 8) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Start and end of each intervention (Week 0, week 4, week 8 and week 12) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by the subjects and investigator (4-point categorical scale) at week 4 and week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Blood Flow</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>IQP-AS-118</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AS-118</intervention_name>
    <description>1 tablet in the morning</description>
    <arm_group_label>IQP-AS-118</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet in the morning</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Caucasian males and females 45-65 years of age

          2. Body mass index (BMI) of 25.0-29.9 kg/m2

          3. Blood pressure (BP) at screening:

               -  systolic blood pressure (SBP) ≤ 140 mmHg or

               -  diastolic blood pressure (DBP) ≤ 90 mmHg

          4. EndoPAT score: ≤ 2.00) at screening

          5. Generally in good health, in particular an electrocardiogram (ECG) without
             pathological findings at screening

          6. Readiness to comply with study procedures, in particular:

               -  Consumption of the investigational product (IP) / placebo according to
                  investigator's advise

               -  Maintaining the same level of physical activity and usual diet during the entire
                  study

               -  Accepting blood draws

               -  Able to undergo an EndoPAT assessment

               -  Complying with visits and all respective requirements for BP and EndoPAT
                  measurements

               -  Filling in diaries/questionnaires

          7. Non-smoker since at least 6 months prior to screening and during the study

          8. Stable body weight in the last 3 months prior to screening (&lt;3 kg self-reported
             change) and during the study

          9. Concomitant medications must have been stable at least during the last 1 month prior
             to screening, if applicable

         10. In women: postmenopausal for at least 12 months Participation is based upon written
             informed consent form (ICF) by the participant following written and oral information
             by the investigator regarding nature, purpose, consequences and possible risks of the
             clinical study.

        Exclusion Criteria:

          1. Known sensitivity to any components of the IP

          2. Known primary or secondary hypertension or white-coat hypertension

          3. Known impaired endothelial function as per investigator's judgement

          4. Clinically significant disturbances in lipid metabolism e.g. known genetic
             hyperlipidemia

          5. Known type-1 / type-2-diabetes

          6. Untreated or non-stabilized thyroid disorder

          7. History and/or presence of clinically significant cardiovascular disease as per
             investigator's judgement:

               1. Known congenital heart defects

               2. Myocardial infarction, heart failure, angina pectoris, life-threatening
                  arrhythmia or stroke within the last 6 months prior to screening

               3. Existing thrombosis or disposition to thrombosis

          8. Any other known significant or serious condition / disease that renders subjects
             ineligible, e.g.:

               1. History of malignancy within ≤5 years prior to screening

               2. Bleeding disorder and/or need for anticoagulants or anti-platelet agents

               3. Current psychiatric care and/or use of neuroleptics

               4. Bariatric surgery in the last 12 months prior to screening

          9. Any known metabolic disease, gastrointestinal disorder or other clinically significant
             disease/disorder which in the investigator's opinion could interfere with the results
             of the study or the safety of the subject

         10. Known arm lymphedema (e.g. due to mastectomy)

         11. Other clinically relevant excursions of safety parameters or any other clinically
             significant abnormality in hematology and/or biochemistry at the Investigator's
             judgement

         12. Dietary habits and/or restrictions that may affect the study outcome

         13. Eating disorder or participation in a weight loss program

         14. Use of medications (e.g. statins, renin angiotensin system inhibitors, nevibolol,
             carvedilol, calcium channel blockers) or supplements that can influence vascular
             endothelial function and/or blood flow (e.g. garlic, cocoa) within the last 4 weeks
             prior to screening and during the study

         15. Use of antiplatelet agents and / or anticoagulants (e.g. warfarin, acetylsalicylic
             acid) within the last 4 weeks prior to screening and during the study

         16. Use of medications or supplements that can influence SBP or DBP (e.g. ACE inhibitors,
             diuretics, calcium channel, α- or ß-blockers, grape seed extract, coenzyme Q10 etc.)
             within the last 4 weeks prior to screening and during the study

         17. Use of lipid lowering medications (affecting lipid metabolism, platelet function or
             antioxidant status, etc.) and/or dietary supplements (e.g. omega-3 fatty acids, green
             tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as
             e.g. Becel), niacin,, glucomannan or chitosan ) within the last 4 weeks prior to
             screening and during the study

         18. Use of medications that can influence cholesterol levels significantly (e.g.
             corticosteroids, amiodarone, estrogen, anabolic steroids) according to investigator's
             judgement

         19. Use of weight loss treatment

         20. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

         21. Drug abuse

         22. Reported participation in night shift work 2 weeks prior to screening and/or during
             the study

         23. Participation in another study or blood donation during the last 30 days prior to
             screening and during the study

         24. Any other reason deemed suitable for exclusion per investigator's judgment, e.g.
             insufficient compliance with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Ulbricht</last_name>
    <phone>+49 30/40 00 81 62</phone>
    <email>mulbricht@analyze-realize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Uebelhack</last_name>
      <phone>+49 30/40 00 81 05</phone>
      <email>ruebelhack@analyze-realize.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

